ArticleAnnals of hematology2025
Long term outcomes of older patients with classical hodgkin lymphoma: an analysis of the Texas cancer registry.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Treatment advances for classical Hodgkin Lymphoma (cHL) have improved outcomes, but studies are lacking in older patients. This analysis aims to investigate survival trends in older individuals with cHL using the Texas Cancer Registry (TCR). Adults ≥ 65 years with cHL were separated into three eras: 1995-2002, 2003-2010, and 2011-2017. Pearson chi-squared test and cox-proportional hazard models along with hazard ratios (HR) and 95% confidence intervals (95% CI) compared demographic factors, and survival trends were assessed by Kaplan-Meier methodology. There were 386 (37.4%), 336 (32.5%), and 311 (30.1%) individuals diagnosed in 1995-2002, 2003-2010, and 2011-2017, respectively. Median DSS per era was 97 months (95% CI 50.7, 143.3), 158 months (95% CI 132.5, 183.5), and not reached, (p=0.383), and median OS was 32 months (95% CI 23.4, 40.6), 37 months (95% CI 23.5, 50.5), and 40 months (95% CI 26.8, 53.1), respectively (p=0.693). Median OS was worse for blacks and Hispanics vs non-Hispanic whites (p=0.007), increasing age (p<0.001), and higher poverty index (p=0.006). While DSS and OS have not improved over the past two decades for older individuals, there are disparity dependent survival differences by race, age, and poverty index. Strategies to reduce these disparities are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.